----item----
version: 1
id: {DEC53D0B-3FA1-4E74-B34D-FB31C87777C5}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/17/BIs Pradaxa antidote idarucizumab wins US priority review
parent: {5262FD33-8196-4910-BCB3-3BC76EEBE076}
name: BIs Pradaxa antidote idarucizumab wins US priority review
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 4ac5456d-71f3-4634-b117-f5f280855c6b

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 194

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{07CF1C44-428A-445B-98D8-5EA9905BD7C5}|{CD796374-A60A-4D81-8A05-7B92AD2013C1}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 60

BI's 'Pradaxa antidote' idarucizumab wins US priority review
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 57

BIs Pradaxa antidote idarucizumab wins US priority review
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1857

<p>The FDA has granted a priority review to Boehringer Ingelheim's biologics license application (BLA) for idarucizumab as an agent to reverse the anticoagulant effect of the firm's blood-thinning agent Pradaxa (dabigatran).</p><p>The idarucizumab BLA is being considered for an accelerated approval.</p><p>There currently are no specific antidotes for newer oral anticoagulants available on the US market, so if the FDA approves idarucizumab, it would be the first.</p><p>Idarucizumab, a fully humanized antibody fragment, or Fab, has been shown to bind specifically to and inhibit Pradaxa with no other expected interactions.</p><p>Pradaxa is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days; and to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated. </p><p>This past June, the FDA designated idarucizumab <a href="http://www.scripintelligence.com/policyregulation/Boehringers-Pradaxa-antidote-idarucizumab-deemed-breakthrough-by-FDA-352537" target="_new">a breakthrough therapy</a> &ndash; a status aimed at expediting the regulatory process of drugs intended to treat serious or life-threatening conditions.</p><p>BI's BLA for idarucizumab is based on Phase I data in volunteers showing that idarucizumab provided immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa. </p><p>Idarucizumab also is being tested in a Phase III global study &ndash; the only trial to examine patients being treated with Pradaxa who are in need of emergency intervention or experience an uncontrolled or life-threatening bleeding event. </p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 228

<p>The FDA has granted a priority review to Boehringer Ingelheim's biologics license application (BLA) for idarucizumab as an agent to reverse the anticoagulant effect of the firm's blood-thinning agent Pradaxa (dabigatran).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 57

BIs Pradaxa antidote idarucizumab wins US priority review
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150417T202946
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150417T202946
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150417T202946
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028524
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 60

BI's 'Pradaxa antidote' idarucizumab wins US priority review
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357946
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042334Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

4ac5456d-71f3-4634-b117-f5f280855c6b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042334Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
